Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0883081
Funder
Australian Research Council
Funding Amount
$350,000.00
Summary
High Content Cell Signaling Discovery and Screening Facility. The national benefits of this facility will be an increase in basic knowledge of how cells transmit signals to determine their behaviour in normal or stressed situations. There will be high impact publications in learned journals, new IP developed, enhanced education and training in cutting edge technologies. The discoveries from this work will provide candidates for development by the Biotechnology industry in Australia. All of this ....High Content Cell Signaling Discovery and Screening Facility. The national benefits of this facility will be an increase in basic knowledge of how cells transmit signals to determine their behaviour in normal or stressed situations. There will be high impact publications in learned journals, new IP developed, enhanced education and training in cutting edge technologies. The discoveries from this work will provide candidates for development by the Biotechnology industry in Australia. All of this will promote an innovation culture and economy. The work done in this facility addresses several National Research Priority areas including Promoting and maintaining good health, Frontier technologies for transforming industry and Safeguarding Australia.Read moreRead less
Pathogen sensing in systemic inflammatory disease. The initiation, amplification and quenching of an immune response is a carefully orchestrated process that eliminates invading pathogens while minimising collateral damage to host tissues. This research focuses on proteins that restrict immune responses to prevent inflammatory diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. This work will also explore the role of a potassium channel that protects the host from or ....Pathogen sensing in systemic inflammatory disease. The initiation, amplification and quenching of an immune response is a carefully orchestrated process that eliminates invading pathogens while minimising collateral damage to host tissues. This research focuses on proteins that restrict immune responses to prevent inflammatory diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. This work will also explore the role of a potassium channel that protects the host from organ failure during an infection, by coupling the energy requirements of mounting an immune response, and organ function. This may have important implications for the management of sepsis, a systemic immune response associated with infection and the leading cause of death in critically ill patients.Read moreRead less
Application of in vivo electroporation to DNA immunisation. The in vivo delivery of plasmid DNA induces immune responses to the encoded protein vaccine. In large animals including humans, DNA vaccination needs to be further improved before becoming a commercial reality, at least partially due to the very low levels of expression in vivo. In vivo electroporation has proven to be an effective way to enhance the level of protein expression and increase DNA vaccine efficacy. We combine enhanced in ....Application of in vivo electroporation to DNA immunisation. The in vivo delivery of plasmid DNA induces immune responses to the encoded protein vaccine. In large animals including humans, DNA vaccination needs to be further improved before becoming a commercial reality, at least partially due to the very low levels of expression in vivo. In vivo electroporation has proven to be an effective way to enhance the level of protein expression and increase DNA vaccine efficacy. We combine enhanced in vivo expression using electroporation with the co-delivery of plasmids encoding cytokines to enhance and modulate DNA vaccine in sheep. We will apply our findings to bovine viral diarrhoea virus (BVDV), both as an animal model for humans and as an economically important diseases of livestock.Read moreRead less
Development of purified antibodies that kill virus infected cells. This proposal will develop panels of purified and monoclonal antibodies that kill virus infected cells. These antibodies may show efficacy in preventing HIV infection. This is new technology that could subsequently be harnessed to protect or limit the devastating effects of chronic viruses such as HIV.
Characterisation and development of adjuvants for new generation veterinary and human vaccines. Vaccination is the most successful and cost-effective means of combating infectious diseases in both veterinary and human medicine. This project will increase our understanding of how vaccines work and will help the development of new vaccines against infections in both animals and man. The results of these studies will also increase the competitiveness of Australian scientists in the field of vaccine ....Characterisation and development of adjuvants for new generation veterinary and human vaccines. Vaccination is the most successful and cost-effective means of combating infectious diseases in both veterinary and human medicine. This project will increase our understanding of how vaccines work and will help the development of new vaccines against infections in both animals and man. The results of these studies will also increase the competitiveness of Australian scientists in the field of vaccine research and development.Read moreRead less
Engineering of anti-platelet antibodies for the diagnosis and therapy of infants with bleeding disorders. Foeto-maternal alloimmune thrombocytopenia (FMAIT) is a serious clinical condition where infants suffer potentially fatal bleeding disorders from 14 weeks gestation to 1-2 weeks post delivery. The cause of the disease is through maternal antibodies destroying foetal platelets. Our aim is to produce human antibodies, which will be used as diagnostic agents to screen for the condition in preg ....Engineering of anti-platelet antibodies for the diagnosis and therapy of infants with bleeding disorders. Foeto-maternal alloimmune thrombocytopenia (FMAIT) is a serious clinical condition where infants suffer potentially fatal bleeding disorders from 14 weeks gestation to 1-2 weeks post delivery. The cause of the disease is through maternal antibodies destroying foetal platelets. Our aim is to produce human antibodies, which will be used as diagnostic agents to screen for the condition in pregnant women, and to further develop such antibodies for therapy. Identification of mothers at risk of FMAIT and the development of a specific therapy are vital to the management and prevention of this serious condition.Read moreRead less